Hematopoietic toxicity study of Zevalin [ibritumomab tiuxetan Y-90] treated patients with non-Hodgkin's lymphoma
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 19 Feb 2007
At a glance
- Drugs Ibritumomab tiuxetan (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 19 Feb 2007 New trial record.